

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Medical & HealthCare Group Limited

(Incorporated in Bermuda with limited liability)

(Stock Code: 383)

POSITIVE PROFIT ALERT

This announcement is made by China Medical & HealthCare Group Limited (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on its preliminary review on the relevant unaudited consolidated management accounts of the Group for the eleven months ended 30 November 2023 and information currently available, subject to any impairment adjustment(s), fair value change and/or provision adjustment(s) on properties or other adjustment(s), the Group is expected to record a profit attributable to Shareholders in the estimated range of approximately HK\$11 million to HK\$31 million for the eleven months ended 30 November 2023 as compared with (a) the loss for the corresponding period in 2022; and (b) the loss of approximately HK\$123.6 million for the year ended 31 December 2022. This was mainly due to (i) the increase in revenue from operations of the healthcare division amid the relaxation of epidemic preventive measures and the resumption of economic and social activities in the Peoples’ Republic of China; (ii) the decrease in cost of medical consumables; and (iii) the increase in interest income from bank deposits but were partially off-set by (iv) the increase in cost of pharmaceutical and medicine; and (v) the increase in employee benefits expense.

This announcement is only based on the preliminary review on the relevant unaudited consolidated management accounts of the Group for the eleven months ended 30 November 2023 and information currently available, which have not been audited or reviewed by the auditor nor reviewed by the audit committee of the Company, and therefore is subject to adjustments where necessary. Accordingly, the actual results of the Group for the year ended 31 December 2023 may be different from what is disclosed in this announcement. The Company is in the process of finalizing the annual results for the year ended 31 December 2023 and Shareholders and potential investors are advised to read carefully the annual results announcement of the Company for the year ended 31 December 2023, which is expected to be released before the end of March 2024.

Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By Order of the Board
China Medical & HealthCare Group Limited
Kong Muk Yin
Executive Director

Hong Kong, 9 January 2024

As at the date of this announcement, the Board comprises Mr. Kong Muk Yin, Mr. Guo Meibao and Mr. Zhou Haiying being Executive Directors; Mr. Lee Seng Hui (Chairman), Mr. Mark Wong Tai Chun and Mr. Gao Zhaoyuan being Non-Executive Directors; and Mr. Zhang Jian, Dr. Xia Xiaoning, Dr. Wong Wing Kuen, Albert and Ms. Yang Lai Sum, Lisa being Independent Non-Executive Directors.